Development of myocardial microcirculation and metabolism in acute ST-elevation myocardial infarction evaluated with positron emission tomography

Journal of Nuclear Cardiology

Volumn 12, Issue 1, 2005, Pages 43-54

  Frostfeldt, Gunnar ^a   Sörensen, Jens ^a,b   Lindahl, Bertil ^a   Valind, Sven ^a   Wallentin, Lars ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Uppsala Imanet   (Sweden)

Author keywords

Myocardial infarction; Positron emission tomography; Water perfusable tissue fraction

Indexed keywords

ACETIC ACID C 11; ACETYLSALICYLIC ACID; ALTEPLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DALTEPARIN; DIPEPTIDYL CARBOXYPEPTIDASE; DOBUTAMINE; FIBRINOLYTIC AGENT; FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLYCERYL TRINITRATE; HEPARIN; OXYGEN; OXYGEN 15; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; AEROBIC METABOLISM; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CORONARY REPERFUSION; DIAGNOSTIC VALUE; FEMALE; GLUCOSE UTILIZATION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE INJURY; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; LUNG FLUID; MALE; MICROCIRCULATION; OXYGEN CONSUMPTION; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; ST SEGMENT ELEVATION; STRESS ECHOCARDIOGRAPHY; SWEDEN; TISSUE PERFUSION;

AGED; CORONARY CIRCULATION; ENERGY METABOLISM; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MICROCIRCULATION; MIDDLE AGED; MYOCARDIAL INFARCTION; OXYGEN; OXYGEN CONSUMPTION; OXYGEN RADIOISOTOPES; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 12744255411     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nuclcard.2004.09.018     Document Type: Article

References (39)

1. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med 1993;329:1615-22
2. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994;343:311-22
3. Barbagelata NA, Granger CB, Oqueli E, Suarez LD, Borruel M, Topol EJ, et al. TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: A pooled analysis. Am Heart J 1997; 133:273-82
4. Simes RJ, Topol EJ, Holmes DR Jr, White HD, Rutsch WR, Vahanian A, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation 1995; 91:1923-8
5. Karagounis L, Sorensen SG, Menlove RL, Moreno F, Anderson JL. Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. Second Multicenter Thrombolysis Trial of Eminase in Acute Myocardial Infarction. J Am Coll Cardiol 1992;19:1-10
6. Anderson JL, Karagounis LA, Becker LC, Sorensen SG, Menlove RL. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circulation 1993;87:1829-39
7. Stadius ML. Angiographic monitoring of reperfusion therapy for acute myocardial infarction. TIMI grade 3 perfusion is the goal. Circulation 1993;87:2055-7
8. Gersh BJ. Optimal management of acute myocardial infarction at the dawn of the next millennium. Am Heart J 1999;138:S188-202
9. Frostfeldt G, Ahlberg G, Gustafsson G, Helmius G, Lindahl B, Nygren A, et al. Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction - a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). J Am Coll Cardiol 1999;33:627-33
10. Maes AF, Van de Werf F, Mesotten LV, Flamen PB, Kuzo RS, Nuyts JL, et al. Early assessment of regional myocardial blood flow and metabolism in thrombolysis in myocardial infarction flow grade 3 reperfused myocardial infarction using carbon-11-acetate. J Am Coll Cardiol 2001 37 30-6
11. Andersson JL. How to obtain high-accuracy image registration: application to movement correction of dynamic positron emission tomography data. Eur J Nucl Med 1998;25:575-86
12. Andersson JL, Thurfjell L. Implementation and validation of a fully automatic system for intra- and interindividual registration of PET brain scans. J Comput Assist Tomogr 1997;21:136-44
13. Chan SY, Brunken RC, Phelps ME, Schelbert HR. Use of the metabolic tracer carbon-11-acetate for evaluation of regional myocardial perfusion. J Nucl Med 1991;32:665-72
14. Bergmann SR, Herrero P, Markham J, Weinheimer CJ, Walsh MN. Noninvasive quantitation of myocardial blood flow in human subjects with oxygen-15-labeled water and positron emission tomography. J Am Coll Cardiol 1989;14:639-52
15. Iida H, Rhodes CG, de Silva R, Yamamoto Y, Araujo LI, Maseri A, Myocardial tissue fraction - correction for partial volume effects measure of tissue viability. J Nucl Med 1991;32:2169-75
16. Velazquez M, Haller J, Amundsen T, Schuster DP. Regional lung water measurements with PET: Accuracy, reproducibility, and linearity. J Nucl Med 1991;32:719-25
17. Sorensen J, Stahle E, Langstrom B, Frostfeldt G, Wikstrom G, Hedenstierna G. Simple and accurate assessment of forward cardiac output by use of 1-(11)C-acetate PET verified in a pig model. J Nucl Med 2003;44:1176-83
18. Porenta G, Cherry S, Czernin J, Brunken R, Kuhle W, Hashimoto T, et al. Noninvasive determination of myocardial blood flow, oxygen consumption and efficiency in normal humans by carbon-11 acetate positron emission tomography imaging. Eur J Nucl Med 1999;26:1465-74
19. van den Hoff J, Burchert W, Borner AR, Fricke H, Kuhnel G, Meyer GJ, et al. [1-(11)C]Acetate as a quantitative perfusion tracer in myocardial PET. J Nucl Med 2001;42:1174-82.
20. van den Hoff J, Burchert W, Wolpers HG, Meyer GJ, Hundeshagen H. A kinetic model for cardiac PET with [1-carbon-11]-acetate. J Nucl Med 1996;37:521-9
21. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983;3:1-7
22. Reffelmann T, Hale SL, Li G, Kloner RA. Relationship between no reflow and infarct size as influenced by the duration of ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2002;282:H766-72
23. 15O-water and dynamic positron emission tomography. Circulation 1992;86:167-78
24. 15O and dynamic positron-emission tomography. Strategy for quantification in relation to the partial-volume effect. Circulation 1988;78:104-15
25. Ambrosio G, Weisman HF, Mannisi JA, Becker LC. Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. Circulation 1989;80:1846-61
26. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002 105 656-62
27. Fabian J, Stolz I, Janota M, Rohac J. Reproducibility of exercise tests in patients with symptomatic ischaemic heart disease. Br Heart J 1975 37 785-9
28. Walsh MN, Geltman EM, Brown MA, Henes CG, Weinheimer CJ, Sobel BE, et al. Noninvasive estimation of regional myocardial oxygen consumption by positron emission tomography with carbon-11 acetate in patients with myocardial infarction. J Nucl Med 1989;30:1798-808
29. Rubin PJ, Lee DS, Davila-Roman VG, Geltman EM, Schechtman KB, Bergmann SR, et al. Superiority of C-11 acetate compared with F-18 fluorodeoxyglucose in predicting myocardial functional recovery by positron emission tomography in patients with acute myocardial infarction. Am J Cardiol 1996;78:1230-5
30. Yamagishi H, Akioka K, Hirata K, Sakanoue Y, Takeuchi K, Yoshikawa J, et al. A reverse flow-metabolism mismatch pattern on PET is related to multivessel disease in patients with acute myocardial infarction. J Nucl Med 1999;40:1492-8
31. Mesotten L, Maes A, Herregods MC, Desmet W, Nuyts J, Van de Werf F, et al. PET "reversed mismatch pattern" early after acute myocardial infarction: Follow-up of flow, metabolism and function. J Nucl Med 2001;28:466-71.
32. Mesotten L, Dispersyn GD, Maes A, Zietkiewicz M, Nuyts J, Bormans G, et al. PET reversed mismatch in an experimental model of subacute myocardial infarction. Eur J Nucl Med 2001; 28:457-65
33. Knaapen P, Boellaard R, Gotte MJ, van der Weerdt AP, Visser CA, Lammertsma AA, et al. The perfusable tissue index: A marker of myocardial viability. J Nucl Cardiol 2003;10:684-91
34. Turschner O, D'Hooge J, Dommke C, Claus P, Verbeken E, De Scheerder I, et al. The sequential changes in myocardial thickness and thickening which occur during acute transmural infarction, infarct reperfusion and the resultant expression of reperfusion injury. Eur Heart J 2004 25 794-803
35. Gavin JB, Maxwell L, Edgar SG. Microvascular involvement in cardiac pathology. J Mol Cell Cardiol 1998;30:2531-40
36. Bax JJ, Fath-Ordoubadi F, Boersma E, Wijns W, Camici PG. Accuracy of PET in predicting functional recovery after revascularisation in patients with chronic ischaemic dysfunction: Head-to-head comparison between blood flow, glucose utilisation and water-perfusable tissue fraction. Eur J Nucl Med Mol Imaging 2002;29:721-7
37. Iida H, Tamura Y, Kitamura K, Bloomfield PM, Eberl S, Ono Y. Histochemical correlates of (15)O-water-perfusable tissue fraction in experimental canine studies of old myocardial infarction. J Nucl Med 2000;41:1737-45
38. Maes A, Van de Werf F, Nuyts J, Bormans G, Desmet W, Mortelmans L. Impaired myocardial tissue perfusion early after successful thrombolysis. Impact on myocardial flow, metabolism, and function at late follow-up. Circulation 1995;92:2072-8
39. Maes A, Mortelmans L, Nuyts J, Bormans G, Herregods MC, Bijnens B, et al. Importance of flow/metabolism studies in predicting late recovery of function following reperfusion in patients with acute myocardial infarction. Eur Heart J 1997;18:954-62